International Psoriasis Council

Advancing Knowledge. Improving Care.

A mature man with short gray hair, a trimmed gray beard, and light skin, wearing a blue collared shirt and dark jacket, poses against a plain gray background, looking directly at the camera with a neutral expression.

Luis

Santamaria-Babí

,

PhD

University of Barcelona
Barcelona
,
Spain
Dr. Luis Santamaria-Babí is a full professor of clinical and translational immunology at the University of Barcelona in Spain. There, he directs a research group at the Barcelona Science Park that is focused on human translational immunology in chronic inflammatory skin diseases. He also serves as an external consultant to the dermatology service at Hospital del Mar in Barcelona. He is involved in undergraduate and postgraduate teaching at the University of Barcelona in clinical immunology, immunopharmacology, knowledge transfer, and biomedical research in the pharmaceutical industry.

For more than three decades, Dr. Santamaria-Babí’s research has focused on the human cutaneous immune system, with particular emphasis on the functional relevance of circulating CLA⁺ memory T cells in atopic dermatitis and other chronic inflammatory skin diseases. In addition to serving as an International Eczema Council (IEC) Councilor, he is on the European Society for Dermatological Research (ESDR) Board, is a member of the Collegium Internationale Allergologicum and the European Dermatology Forum, and serves as an editorial board member for Allergy.

Dr. Santamaria-Babí obtained his PhD at the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos and subsequently worked for 13 years in the pharmaceutical industry as a pharmacologist and project leader, contributing to the identification and development of novel therapeutic targets in chronic inflammation.
Last Updated:
05/07/2026

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026